Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Salivary Gland Neoplasms × pazopanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 42 Sarcoma 20 Neoplasms 18 Neoplasm Metastasis 13 Ovarian Neoplasms 10 Breast Neoplasms 10 Carcinoma, Non-Small-Cell Lung 7 Melanoma 5 Thyroid Neoplasms 4 Hemangiosarcoma 4 Fallopian Tube Neoplasms 4 Urinary Bladder Neoplasms 3 Solid Tumors 3 Recurrence 3 Prostatic Neoplasms 3 Lung Neoplasms 3 Liposarcoma 3 Leiomyosarcoma 3 Kidney Neoplasms 3 Colorectal Neoplasms 3 Clear-cell metastatic renal cell carcinoma 3 Carcinoma, Ovarian Epithelial 3 Sarcoma, Synovial 2 Refractory Solid Tumors 2 Neuroendocrine Tumors 2 Gliosarcoma 2 Glioblastoma 2 Chondrosarcoma, Extraskeletal Myxoid 2 Central Nervous System Neoplasms 2 Brain Neoplasms 2

Interventions

Docetaxel 8 Cisplatin 8 Cetuximab 8 Radiotherapy 7 Erlotinib Hydrochloride 7 Chemotherapy, Adjuvant 6 Paclitaxel 5 Immunohistochemistry 5 Gemcitabine 5 Carboplatin 4 Vorinostat 3 Trastuzumab 3 Surgical Procedures, Operative 3 Sorafenib 3 Radiotherapy, Intensity-Modulated 3 Radiosurgery 3 Irinotecan 3 Doxorubicin 3 Capecitabine 3 Biopsy 3 Bevacizumab 3 sargramostim 2 ixabepilone 2 Taxes 2 SS1(dsFv)PE38 2 Radiotherapy, Conformal 2 Radiation 2 Polymerase Chain Reaction 2 Nivolumab 2 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02393820 2019-10-29

PACSA-ORL02

UNICANCER

Phase 2 Completed

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡